Hoeper MM, Simon R, Gibbs J.- The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev, 2014, 23, 450-457.
Galiè N, Humbert M, Vachiery JL, et al.- 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J, 2016, 37, 67-119.
Simonneau G, Gatzoulis MA, Adatia I, et al.-Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2013, 62, D34-41.
Guignabert C, Tu L, Le Hiress M, et al.- Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev, 2013, 22, 543-551.
Guignabert C, Dorfmuller P.- Pathology and pathobiology of pulmonary hypertension. Semin Respir Crit Care Med, 2013, 34, 551-559.
Hoeper MM, McLaughlin VV, Barberá JA, et al.-Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med, 2016, 4, 894-901.
Boucly A, Weatherald J, Savale L, et al.- Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J, 2017, 50, 1700889.
Liberal R, Grant CR, Baptista R, et al.- 'Porto-pulmonary hypertension: A comprehensive review'. Clin Res Hepatol Gastroenterol, 2015, 39, 157-167.
Seeger W, Adir Y, Barberà JA et al.- Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol, 2013, 62, D109-116.
Hoeper MM, Kramer T, Pan Z, et al.- Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J, 2017, 50, 1700740.
Humbert M, Lau EMT, Montani D, et al.- Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation, 2014, 130, 2189-2208.